Opportunities in the Sickle Cell Disease market include advancing gene-editing therapies like EDIT-301, expanding VOC-reducing treatments such as inclacumab, and exploring novel drug candidates like ...

Sickle cell anemia (HbSS) is the homozygous dominant variant and the most common and severe form of the disease. Whereas patients who only inherited one gene encoding for abnormal HbS and a different ...

Members of Fulcrum management will be joined by Dr. Martin Steinberg, Professor of Medicine, Pediatrics, Pathology and Laboratory Medicine at Boston University Chobanian and Avedisian School of ...

Recent therapies like hydroxyurea (Droxia, Bristol-Myers Squibb), the first FDA-approved drug for SCD in 1994, increase fetal hemoglobin (HbF), which, through unknown pathways, improves SCD symptoms ...

More than two years after its approval, only about 60 patients across the U.S., Middle East, and Europe have been treated with the gene-editing therapy. Specialists at four sickle centers told STAT ...

For most of his 20 years, a New Jersey man knew pain as a daily reality. Now, after a one-time CRISPR gene-editing treatment at Children's Hospital of Philadelphia, Austin Louis says he is finally ...

Two Pee Dee siblings are officially cured of sickle cell disease after more than a decade of living with the genetic blood ...

Black History Month is poignant for one family after a man got a historic, innovative treatment at Children's Hospital of Philadelphia.

WNCT’s Erin Jenkins sits down with a sickle cell disease survivor and a doctor to learn more about how far their research has ...

Music helps break down barriers. Once students connect emotionally, they are more open to understanding what sickle ...

GREENVILLE, N.C. (WNCT) — WNCT’s Erin Jenkins sits down with a sickle cell disease survivor and a doctor to learn more about ...

Austin Louis, 20, says the CRISPR treatment he received at the Children's Hospital of Philadelphia for sickle cell disease ...